Chief Risk Officer DashboardFree Financial Model Download

This Contract Research Organisation (CRO) financial model projects revenue from clinical trial management, consulting services, and laboratory work across multiple therapeutic areas and customer segments. It models active studies by type (oncology, rare disease, etc.), active accounts, consulting utilisation (billable hours, hourly rates), and lab samples processed. Revenue grows from study volume growth, pricing escalation, and customer mix shift toward higher-margin products. The model includes customer concentration risk (top 10 customers), backlog conversion rates, and contract-specific profitability (fixed-price versus FTE/time-and-materials contracts).

The model includes operating expense sections for direct labour (clinical research associates, project managers) scaled to study volumes and account count; fixed overhead (IT, facilities, G&A); business development and marketing; and technology investment (EDC/CTMS platform development). Working capital tracks receivables (55–80 day DSO typical for pharma sponsors), unbilled revenue, and deferred revenue. Capex includes laboratory equipment, office build-outs, and technology platform investment. Key margins include gross margin (after direct labour), EBITDA margin (after overhead absorption), and net margin.

This model is used by CRO management teams forecasting growth and profitability, PE sponsors evaluating CRO acquisition targets, lenders sizing working capital facilities (especially important given material unbilled receivables and payment delays from pharma sponsors), and public equity analysts researching CRO publicly traded stocks. It addresses the unique challenge of labour-intensive, contract-based business models with long customer sales cycles and complex revenue recognition.